First studies under the agreement to focus on clinical trial
programs in oncology
Bristol-Myers
Squibb Company (NYSE: BMY) and Emory
University today announced the formation of a strategic partnership
to conduct clinical trials involving Bristol-Myers Squibb’s
investigational compounds.
Under the newly established Master Clinical Trial Agreement,
investigators from Emory University and affiliated institutions will
conduct Phase II, Phase III and pediatric clinical trials in the
metropolitan Atlanta area to support the ongoing development of
investigational medicines from across Bristol-Myers Squibb’s portfolio,
particularly in oncology, metabolics, hepatitis C and immunoscience.
This agreement builds on recent experiences between the two
organizations in conducting clinical trials in organ transplantation and
cancer.
In the first studies under the new agreement, researchers from the
Winship Cancer Institute of Emory University will work with
Bristol-Myers Squibb scientists on multiple clinical trial programs in
oncology.
“This partnership is aligned with Bristol-Myers Squibb’s strategy, which
embraces the opportunity to selectively integrate the expertise of other
organizations with our own to best meet the treatment needs of
patients,” said Brian
Daniels, senior vice president, Global Development & Medical
Affairs, Bristol-Myers Squibb. “Our expectation is that the shared
commitment of providing innovative solutions for patients, the
world-class talent at both organizations and the clinical trial
expertise at Emory, will result in important advancements in the
understanding of Bristol-Myers Squibb compounds and their potential for
treating patients with devastating diseases, such as cancer.”
“Through this partnership, we are working to provide a framework to
improve clinical trials efficiency and to enhance the development of
academic and industry collaborations that solve health care problems,”
says David S. Stephens, MD, vice president for research in Emory’s
Woodruff Health Sciences Center and principal investigator of the
Atlanta Clinical and Translational Science Institute (ACTSI). “Emory’s
successful partnership with Bristol-Myers Squibb in developing drugs for
organ transplantation is an excellent example of the benefits of these
kinds of collaborations.”
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information, please
visit
www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.
For more information on our clinical trials, please visit www.
bms.com/clinical_trials.
About Emory University
Emory University is a leading educational and research institution that
includes nine highly ranked colleges and professional schools and the
state's most comprehensive health system. Emory's Woodruff Health
Sciences Center is pioneering new ways to prevent and treat
disease, driving technology-based economic development through
translation of research into life-saving products, serving the local and
global communities, and preparing the next generation to save and
improve lives.
